The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji.
Journal
The Lancet regional health. Western Pacific
ISSN: 2666-6065
Titre abrégé: Lancet Reg Health West Pac
Pays: England
ID NLM: 101774968
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
entrez:
14
1
2022
pubmed:
15
1
2022
medline:
15
1
2022
Statut:
epublish
Résumé
In 2012, Fiji introduced the 10-valent pneumococcal conjugate vaccine (PCV10). We assessed the impact of PCV10 on invasive pneumococcal disease (IPD), probable bacterial or pneumococcal meningitis (PBPM), meningitis and sepsis 3-5 years post-introduction. Laboratory-confirmed IPD and PBPM cases were extracted from national laboratory records. ICD-10-AM coded all-cause meningitis and sepsis cases were extracted from national hospitalisation records. Incidence rate ratios were used to compare outcomes pre/post-PCV10, stratified by age groups: 1-23m, 2-4y, 5-9y, 10-19y, 20-54y, ≥55y. To account for different detection and serotyping methods in the pre-and post-PCV10 period, a Bayesian inference model estimated serotype-specific changes in IPD, using pneumococcal carriage and surveillance data. There were 423 IPD, 1,029 PBPM, 1,391 all-cause meningitis and 7,611 all-cause sepsis cases. Five years post-PCV10 introduction, IPD declined by 60% (95%CI: 37%, 76%) in children 1-23m months old, and in age groups 2-4y, 5-9y, 10-19y although confidence intervals spanned zero. PBPM declined by 36% (95%CI: 21%, 48%) among children 1-23 months old, and in all other age groups, although some confidence intervals spanned zero. Among children <5y of age, PCV10-type IPD declined by 83% (95%CI; 70%, 90%) and with no evidence of change in non-PCV10-type IPD (9%, 95%CI; -69, 43%). There was no change in all-cause meningitis or sepsis. Post-PCV10, the most common serotypes in vaccine age-eligible and non-age eligible people were serotypes 8 and 23B, and 3 and 7F, respectively. Our study demonstrates the effectiveness of PCV10 against IPD in a country in the Asia-Pacific of which there is a paucity of data. This study was support by the Department of Foreign Affairs and Trade of the Australian Government and Fiji Health Sector Support Program (FHSSP). FHSSP is implemented by Abt JTA on behalf of the Australian Government.
Sections du résumé
BACKGROUND
BACKGROUND
In 2012, Fiji introduced the 10-valent pneumococcal conjugate vaccine (PCV10). We assessed the impact of PCV10 on invasive pneumococcal disease (IPD), probable bacterial or pneumococcal meningitis (PBPM), meningitis and sepsis 3-5 years post-introduction.
METHODS
METHODS
Laboratory-confirmed IPD and PBPM cases were extracted from national laboratory records. ICD-10-AM coded all-cause meningitis and sepsis cases were extracted from national hospitalisation records. Incidence rate ratios were used to compare outcomes pre/post-PCV10, stratified by age groups: 1-23m, 2-4y, 5-9y, 10-19y, 20-54y, ≥55y. To account for different detection and serotyping methods in the pre-and post-PCV10 period, a Bayesian inference model estimated serotype-specific changes in IPD, using pneumococcal carriage and surveillance data.
FINDINGS
RESULTS
There were 423 IPD, 1,029 PBPM, 1,391 all-cause meningitis and 7,611 all-cause sepsis cases. Five years post-PCV10 introduction, IPD declined by 60% (95%CI: 37%, 76%) in children 1-23m months old, and in age groups 2-4y, 5-9y, 10-19y although confidence intervals spanned zero. PBPM declined by 36% (95%CI: 21%, 48%) among children 1-23 months old, and in all other age groups, although some confidence intervals spanned zero. Among children <5y of age, PCV10-type IPD declined by 83% (95%CI; 70%, 90%) and with no evidence of change in non-PCV10-type IPD (9%, 95%CI; -69, 43%). There was no change in all-cause meningitis or sepsis. Post-PCV10, the most common serotypes in vaccine age-eligible and non-age eligible people were serotypes 8 and 23B, and 3 and 7F, respectively.
INTERPRETATIONS
CONCLUSIONS
Our study demonstrates the effectiveness of PCV10 against IPD in a country in the Asia-Pacific of which there is a paucity of data.
FUNDING
BACKGROUND
This study was support by the Department of Foreign Affairs and Trade of the Australian Government and Fiji Health Sector Support Program (FHSSP). FHSSP is implemented by Abt JTA on behalf of the Australian Government.
Identifiants
pubmed: 35028629
doi: 10.1016/j.lanwpc.2021.100352
pii: S2666-6065(21)00261-3
pmc: PMC8741523
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100352Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationshipsthat could have appeared to influence the work reported in this paper.
Références
Clin Infect Dis. 2019 May 30;68(12):2135-2143
pubmed: 30357326
Clin Infect Dis. 2019 Sep 5;69(Suppl 2):S58-S65
pubmed: 31505628
J Vis Exp. 2014 Sep 25;(91):51747
pubmed: 25285991
Rev Panam Salud Publica. 2018 Sep 24;42:e155
pubmed: 31093183
PLoS One. 2016 Dec 12;11(12):e0166736
pubmed: 27941979
Vaccine. 2017 Nov 7;35(47):6416-6421
pubmed: 29037577
Lancet Glob Health. 2018 Dec;6(12):e1375-e1385
pubmed: 30420033
Nat Rev Microbiol. 2018 Jun;16(6):355-367
pubmed: 29599457
Cad Saude Publica. 2015 Feb;31(2):276-84
pubmed: 25760162
Expert Rev Vaccines. 2017 Oct;16(10):1007-1027
pubmed: 28783380
Am J Epidemiol. 2016 Nov 1;184(9):652-659
pubmed: 27744387
Pediatrics. 2015 Jul;136(1):e22-7
pubmed: 26077477
J Clin Microbiol. 2006 Sep;44(9):3346-51
pubmed: 16954271
Clin Infect Dis. 2019 Sep 5;69(Suppl 2):S121-S125
pubmed: 31505632
J Vis Exp. 2014 Feb 24;(84):e51208
pubmed: 24637727
Pediatr Infect Dis J. 2010 Sep;29(9):870-2
pubmed: 20622710
J Pediatr. 2019 Oct;213:252-253.e3
pubmed: 31561776
PLoS Med. 2011 Apr;8(4):e1001017
pubmed: 21483718
Vaccine. 2016 May 27;34(25):2766-78
pubmed: 27113162
Popul Health Metr. 2016 Nov 25;14:45
pubmed: 27905979
PLoS Comput Biol. 2014 Feb 13;10(2):e1003477
pubmed: 24550722
PLoS Comput Biol. 2015 Apr 16;11(4):e1004173
pubmed: 25879748
Sci Rep. 2016 Dec 23;6:39784
pubmed: 28009001
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Pediatr Infect Dis J. 2019 Aug;38(8):860-865
pubmed: 30985507
Vaccine. 2018 Apr 5;36(15):1934-1940
pubmed: 29526371
Am J Epidemiol. 2013 Nov 1;178(9):1488-95
pubmed: 24013204
Lancet Glob Health. 2017 Jan;5(1):e51-e59
pubmed: 27955789
Lancet. 2019 May 25;393(10186):2146-2154
pubmed: 31000194